Miach Orthopaedics, Inc., a cutting-edge company dedicated to revolutionizing soft tissue repair in orthopedics, announced that it has successfully raised $20 million in funding. This significant investment will enable the company to further advance its mission of redefining the approach to rotator cuff repair by enhancing initial repair strength and facilitating optimal healing conditions. Miach Orthopaedics' innovative device is designed to address crucial factors for tendon healing, including immediate strength, minimal tendon mobility, broad points of fixation, and an optimal biologic environment. With a team of experienced founders who have a proven track record in enhancing patient care, including successful past endeavors such as Rotation Medical, the company is poised to make a transformative impact in the orthopedic field. The funding will support Miach Orthopaedics in driving forward its groundbreaking technology and bringing about positive changes in soft tissue repair procedures for patients and healthcare providers alike.
Revolutionizing Rotator Cuff Repair: Integrity Orthopaedics Secures $20M in Series B Funding
Recently funded 路 $20.0M Series bMedical Equipment Manufacturing
Get the full Miach Orthopaedics, Inc. company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Aisot Technologies
Aisot Technologies is a Zurich-based AI company pioneering advanced, AI-driven investment solutions. Spun out of ETH Zurich in 2021, aisot leverages machine learning, large language models (LLMs), and quantitative methods to deliver precise, real-time investment insights. Its AI Insights Platform empowers asset managers, funds, family offices, and treasuries to anticipate market trends, optimize strategies, and mitigate risk. Recognized across Europe and the U.S., aisot partners with leading financial institutions to redefine quantitative investment management.
$2.5M Seed
today
Dognosis
Dognosis is a deep-tech startup in Bangalore decoding canine cognition to reveal the hidden world of scent. Our vision is a world where we have cracked the olfactory code of disease, making detecting disease as easy as breathing. Our mission is to save lives by detecting disease early and advance humanity towards truly proactive and preventative medicine. Our work revolves around increasing the bandwidth of human-canine collaboration, allowing us to catch the scent of disease at scale. Our first goal is to solve for early cancer detection by pioneering a multi-cancer breath-based test - BreathEasy - that will be ultra-affordable, highly accurate, and super accessible. We're always on the lookout for passionate and ambitious people to work with us. Feel free to say hi to woof@dognosis.tech
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  NEW ID | Series b | $705.2K | today |
| 2 |  Arist United States | Series b | $14.1M | today |
| 3 |
